Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
GeneFerm Biotechnology CoROCO:1796 -1.26%65 Interest Coverage is 11.81 as of Dec. 2025, which is 37% below its 10-year median of 18.74. GuruFocus rates ROCO:1796 with a GF Score™ of 65/100 and a GF Value™ of NT$59.04 (Significantly Undervalued). The stock has 6 warning signs investors should review. Among 687 Drug Manufacturers companies, GeneFerm Biotechnology Co ranks worse than 61.43% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. GeneFerm Biotechnology Co's
Operating Income
for the
three
months ended in Dec. 2025 was NT$18.4 Mil. GeneFerm Biotechnology Co's Interest Expense for the
three
months ended in Dec. 2025 was NT$-1.6 Mil.
GeneFerm Biotechnology Co's interest coverage for the quarter that ended in Dec. 2025 was 11.81.
The higher the ratio, the stronger the company's financial strength is.
The historical rank and industry rank for GeneFerm Biotechnology Co's Interest Coverage or its related term are showing as below:
ROCO:1796'
s Interest Coverage Range Over the Past 10 Years
Min: 1.84 Med: 18.74 Max: 78.83
Current: 7.4
ROCO:1796's Interest Coverage is ranked worse than 61.43% of 687
companies
in the Drug Manufacturers industry
Industry Median: 12.75
vs ROCO:1796: 7.40
GeneFerm Biotechnology Co (ROCO:1796) Interest Coverage Explanation
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
GeneFerm Biotechnology Co Interest Coverage Related Terms
GeneFerm Biotechnology Co Interest Coverage Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
ROCO:1796 vs ZTS, UTHR: Interest Coverage Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, GeneFerm Biotechnology Co's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
GeneFerm Biotechnology Co Interest Coverage vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, GeneFerm Biotechnology Co's Interest Coverage distribution charts can be found below:
* The bar in red indicates where GeneFerm Biotechnology Co's Interest Coverage falls into.
GeneFerm Biotechnology Co Interest Coverage Calculation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GeneFerm Biotechnology Co (ROCO:1796) has a Interest Coverage of 11.81 as of Dec. 2025. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on GeneFerm Biotechnology Co and its competitors. This is 37% below median its historical median of 18.74. Over the past decade, GeneFerm Biotechnology Co's Interest Coverage has ranged from 1.84 to 78.83. According to the industry distribution chart, GeneFerm Biotechnology Co ranks #422 out of 687 companies in the Drug Manufacturers industry, placing it in the top 61.4%.
Is GeneFerm Biotechnology Co's Interest Coverage too high?
GeneFerm Biotechnology Co's current Interest Coverage of 11.81 is 37% below median its 10-year median of 18.74. Over the past 10 years, this metric has ranged from a low of 1.84 to a high of 78.83. The Drug Manufacturers industry median Interest Coverage is 12.75. GeneFerm Biotechnology Co's value of 11.81 is 7.4% below this industry median. Based on the distribution chart, GeneFerm Biotechnology Co ranks #422 out of 687 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, GeneFerm Biotechnology Co has a GF Score™ of 65/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does GeneFerm Biotechnology Co's Interest Coverage compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, GeneFerm Biotechnology Co ranks #422 out of 687 companies for Interest Coverage. This places GeneFerm Biotechnology Co in the lower half of its industry. The industry median Interest Coverage is 12.75. GeneFerm Biotechnology Co's value of 11.81 is 7.4% below this benchmark. Historically, GeneFerm Biotechnology Co's own Interest Coverage has ranged from 1.84 to 78.83 over the past decade. While the company's 10-year median is 18.74 vs. the industry median of 12.75, GeneFerm Biotechnology Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Drug Manufacturers company?
The median Interest Coverage among Drug Manufacturers companies is 12.75, based on 687 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. GeneFerm Biotechnology Co's current Interest Coverage of 11.81 is 7.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on GeneFerm Biotechnology Co and its competitors. For the Drug Manufacturers industry, the median Interest Coverage is 12.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. GeneFerm Biotechnology Co's current Interest Coverage is 11.81, which is 37% below median its own 10-year median of 18.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GeneFerm Biotechnology Co stock overvalued right now?
Based on GuruFocus' analysis, GeneFerm Biotechnology Co (ROCO:1796) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$59.04, compared to a current price of NT$31.40 — trading 46.8% below its estimated fair value. The current Interest Coverage is 11.81, which is 37% below median its 10-year median of 18.74 and 7.4% below the Drug Manufacturers industry median of 12.75. GeneFerm Biotechnology Co's overall GF Score™ is 65/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For GeneFerm Biotechnology Co (ROCO:1796), the current Interest Coverage is 11.81 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is GeneFerm Biotechnology Co (ROCO:1796) Overvalued in 2026?
Based on GuruFocus' analysis, GeneFerm Biotechnology Co stock appears to be undervalued.
The current stock price of NT$31.40 is trading 46.8% below its estimated GF Value™ of NT$59.04.
GuruFocus considers GeneFerm Biotechnology Co to be Significantly Undervalued.
Key valuation signals for ROCO:1796:
Interest Coverage: 11.81 (37% below median its 10-year median of 18.74)
GF Value™: NT$59.04 vs. price of NT$31.40 (46.8% below fair value)
Industry Position: 7.4% below the Drug Manufacturers median (#422 of 687)
No single metric tells the full story. See the ROCO:1796 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
GeneFerm Biotechnology Co Ltd is a fermentation company based in Taiwan. It is engaged in manufacturing health food and supplements which include Fermented Microbial products, Fermented Fungi products, Probiotics and Extraction, and Concentration products among others.
65GF Score
Get the complete analysis for ROCO:1796
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:1796 has been successfully added to your 
